Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Nivolumab significantly improved median RFS and DMFS compared to ipilimumab in resected stage IIIB to IIIC or IV melanoma patients. The study suggested potential benefits of morning dosing, with ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months.

A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. is conducting a clinical ...

Overall survival was significantly better with the combination therapy, achieving 23.1 months versus 19.6 months with PHP alone. Combination therapy of percutaneous hepatic perfusion with immune ...

Replimune's RP1 BLA for advanced melanoma gets FDA review, sparking REPL stock surge. Click here to read why REPL stock is ...

Immunotherapy against melanoma is more effective and has fewer side effects when administered in the morning. This is one of ...